ML130, also known as Nodinitib-1, is primarily utilized in biochemical research as a potent and selective inhibitor of the NOD1 (nucleotide-binding oligomerization domain-containing protein 1) pathway. It is widely employed in studies aimed at understanding the role of NOD1 in immune responses, particularly in the context of inflammation and host defense mechanisms. Researchers use ML130 to investigate how NOD1 signaling contributes to the recognition of bacterial pathogens and the subsequent activation of immune pathways. Additionally, it serves as a valuable tool in exploring potential therapeutic strategies for diseases where NOD1 activity is implicated, such as inflammatory bowel disease, autoimmune disorders, and certain infections. Its specificity makes it a critical compound for dissecting the complex interactions within innate immunity.